EPA honors Merck and Codexis with Presidential Green Chemistry Challenge Award

Merck and Codexis, Inc. (NASDAQ:CDXS) today announced that they have jointly been awarded the annual Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) for the development of a novel biocatalytic method for the synthesis of sitagliptin. In addition, a paper co-authored by Merck and Codexis scientists and published online June 17 in the peer-reviewed journal Science, details how an enzyme was systematically customized using Codexis technology to perform the key chemical step in the sitagliptin synthesis process. This process showed improved efficiency and significantly decreased chemical waste byproducts.

“Our proven technology platform is in use around the world, enabling creation of cleaner, more efficient pharmaceutical manufacturing processes. We are committed, with our colleagues at Merck, to leveraging the power of green chemistry for a sustainable environment.”

"Merck has a longstanding commitment to environmental sustainability," said Richard Tillyer, Ph.D, head of Drug Discovery and Preclinical Sciences, Merck Research Laboratories. "This award and the recent publication underscore the strength of the innovative science and the productive collaboration with our colleagues at Codexis."

The publication in Science outlines how Merck and Codexis collaborated to create a custom enzyme, or biocatalyst, that can allow for commercial-scale manufacturing of sitagliptin. No natural enzyme able to produce this compound was found. Enzymes are biodegradable, renewable and are generally believed to provide a more sustainable means of chemical synthesis than many currently employed methods used for the manufacture of pharmaceuticals. Evidence suggests that the new process may offer a 10-13 percent overall increase in yield of sitagliptin over the current process and a significant reduction in waste byproducts.

"Codexis is honored to receive one of the U.S. government's highest awards for environmental protection with Merck," said Alan Shaw, Ph.D., Codexis President and CEO. "Our proven technology platform is in use around the world, enabling creation of cleaner, more efficient pharmaceutical manufacturing processes. We are committed, with our colleagues at Merck, to leveraging the power of green chemistry for a sustainable environment."

Source:

Codexis, Inc.

Advertisement

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
FDA approves marijuana based medication for epilepsy treatment